COMMUNIQUÉS West-GlobeNewswire

XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board
12/09/2018
AUSTIN, Texas, Sept. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) is pleased to announce the appointment of Peter Libby, MD to its Scientific Advisory Board (SAB). Dr. Libby will work with XBiotech to help [...]
Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership
12/09/2018
Partnership Involves Commercial-scale Production of hRS7, the Antibody Used in Immunomedics’ Lead Antibody-Drug Conjugate, Sacituzumab Govitecan MORRIS PLAINS, N.J. and INCHEON, South Korea, Sept. 12, 2018 (GLOBE [...]
Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects
12/09/2018
BUFFALO, N.Y., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Emblem signs supply agreement with Aphria to purchase up to 175,000 kg equivalents of cannabis products over five years
12/09/2018
TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), through its wholly-owned subsidiary Emblem Cannabis Corporation, a licensed producer of medical cannabis [...]
Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program
12/09/2018
ANAHEIM, CA, Sept. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today [...]
MRI Interventions to Present at Sidoti & Co. 2018 Fall Conference on Sept 27
12/09/2018
LOS ANGELES, Sept. 12, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC), announced today that Chief Executive Officer Joe Burnett will present at the Sidoti & Co. 2018 Fall Conference on Thursday, [...]
Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
12/09/2018
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Helix BioPharma Corp. collaborator ProMab Biotechnologies Publishes Paper on Multiple Myeloma CAR-T
12/09/2018
RICHMOND HILL, Ontario, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]
Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings
12/09/2018
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target Conference Updated data from the TTI-621 intralesional trial in patients with mycosis fungoides and Sézary [...]
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12/09/2018
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the [...]
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
12/09/2018
FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions [...]
Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
12/09/2018
MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, a specialty pharmaceutical [...]
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth
12/09/2018
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth Research Triangle Park, NC and Cambridge, UK, September 12, 2018 -- Inivata , a leader in liquid biopsy, today announces the strengthening of [...]
Aleafia Completes Second Harvest with Sale to Licensed Producer Imminent
12/09/2018
Clinic Operations and Cannabis Sales Providing Immediate Multiple Income Streams TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one [...]
Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
12/09/2018
- Former CMO of Schering-Plough Joins Cyclacel Board - BERKELEY HEIGHTS, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a [...]
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
12/09/2018
-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of [...]
Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).
12/09/2018
Press release Malmö, September 12, 2018 Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD). Acarix AB (publ) ("Acarix") reports first sales in [...]
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
12/09/2018
SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]
Solon Eiendom ASA – Primary insider notification
12/09/2018
(Oslo, Norway, September 11, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 30.000 shares in Solon Eiendom ASA at a price of NOK 29. Following this [...]

Pages